选择语言

HRSV (A) Pre-fusion glycoprotein F0, His Tag (MALS verified)

用户评价
货号-规格
价格
Qty.
RSF-V52H7-50ug
¥4725.00
RSF-V52H7-500ug
¥29400.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    Prefusion glycoprotein F0/pre-F protein (RSV)

  • 表达区间及表达系统(Source)

    HRSV (A) Fusion glycoprotein F0, His Tag (RSF-V52H7) is expressed from human 293 cells (HEK293).

    Predicted N-terminus: Gln 26

  • 蛋白结构(Molecular Characterization)

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 56.1 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Unconjugated

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method.

  • 纯度(Purity)

    95% as determined by SDS-PAGE.

    90% as determined by SEC-MALS.

  • 制剂(Formulation)

    Supplied as 0.2 μm filtered solution in 0.1 M Sodium citrate, 150 mM NaCl, pH5.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 运输(Shipping)

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • 存储(Storage)

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 电泳(SDS-PAGE)

    Prefusion glycoprotein F0/pre-F protein (RSV) SDS-PAGE

    HRSV (A) Pre-fusion glycoprotein F0, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    Prefusion glycoprotein F0/pre-F protein (RSV) SEC-MALS

    The purity of HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) is more than 90% and the molecular weight of this protein is around 175-200 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) with a linear range of 0.2-1 ng/mL (QC tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized Monoclonal Anti-HRSV F Antibody, Human IgG1 (AM14) (Cat. No. HRF-S367) at 1 μg/mL (100 μL/well) can bind HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) with a linear range of 0.2-16 ng/mL (QC tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (MALS verified) (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (3B4) with a linear range of 0.098-3.125 ng/mL (Routinely tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (MALS verified) (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (4G2) with a linear range of 0.024-0.781 ng/mL (Routinely tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) with a linear range of 0.2-5 ng/mL (Routinely tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) at 2 μg/mL (100 μL/well) can bind HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) with a linear range of 0.1-13 ng/mL (Routinely tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized Nirsevimab, Human IgG1 kappa at 1 μg/mL (100 μL/well) can bind HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) with a linear range of 0.2-8 ng/mL (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

前沿进展

 
联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍